Association of clinicopathological features with E-cadherin (CDH1) gene-160 C>A promoter polymorphism in Turkish colorectal cancer patients

Basit Öğe Kaydı
dc.authoridbudak, metin/0000-0002-5968-2048
dc.authorwosidBudak, metin/Z-3010-2019
dc.contributor.authorBahadir, Anzel
dc.contributor.authorEral, Gokalp
dc.contributor.authorBudak, Metin
dc.contributor.authorShimamoto, Fumio
dc.contributor.authorKorpinar, Mehmet Ali
dc.contributor.authorErdamar, Sibel
dc.contributor.authorTuncel, Handan
dc.date.accessioned2024-06-12T10:56:40Z
dc.date.available2024-06-12T10:56:40Z
dc.date.issued2019
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground and Aim of Study: The role of E-cadherin (CDH1) gene-160 C>A (rsl 6260) promoter polymorphism in colorectal cancer (CRC) still remains inconclusive. The aim of this study is to investigate the associations between the CDH1 -160 C>A polymorphism with the susceptibility and clinicopathological development of CRC in the Turkish patients. To our knowledge, this is the first report examining the role of CDH1 polymorphism in Turkish CRC patients. Materials and Methods: A total of 92 colorectal carcinoma cases (including 62 colon and 30 rectal cancer patients) and the corresponding adjacent normal tissues as controls were studied. The polymorphism was genotyped using polymerase chain reaction-restriction fragment length polymorphism analysis. Clinicopathological features including patient's age, gender, tumor stage, and tumor location (colon/ rectum) were compared statistically with the polymorphism status. Results: There was no significant difference in both genotype and allele frequencies of the CDH1 polymorphism between colorectal tumor cases and normal samples (P = 0.472 and 0.508, respectively). Furthermore, no significant associations were observed between the CDH1 polymorphism status and age, gender, tumor stage, and tumor location of the colorectal tumor cases (all P>0.05). Conclusions: These results indicate that CDH1 -160 C>A polymorphism does not contribute to the genetic susceptibility of CRC and the polymorphism may not be a direct effect on the progression of the disease in Turkish CRC patients.en_US
dc.description.sponsorshipIstanbul University Cerrahpasa Medical Faculty Hospital, Istanbul, Turkeyen_US
dc.description.sponsorshipThis study was financially supported by Istanbul University Cerrahpasa Medical Faculty Hospital, Istanbul, Turkeyen_US
dc.identifier.doi10.4103/jcrt.JCRT_1277_16
dc.identifier.endpage31en_US
dc.identifier.issn0973-1482
dc.identifier.issn1998-4138
dc.identifier.issue1en_US
dc.identifier.pmid30880750en_US
dc.identifier.scopus2-s2.0-85063199603en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage26en_US
dc.identifier.urihttps://doi.org/10.4103/jcrt.JCRT_1277_16
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19879
dc.identifier.volume15en_US
dc.identifier.wosWOS:000461542500005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofJournal Of Cancer Research And Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectClinicopathological Featuresen_US
dc.subjectColorectal Canceren_US
dc.subjectE-Cadherin (CDH1)-160 C > A Polymorphismen_US
dc.subjectPolymerase Chain Reaction-Restriction Fragment Length Polymorphism Analysisen_US
dc.subjectSusceptibilityen_US
dc.subjectSingle Nucleotide Polymorphismen_US
dc.subjectCyclin D1 Ccnd1en_US
dc.subjectRisken_US
dc.subjectAdhesionen_US
dc.subjectExpressionen_US
dc.titleAssociation of clinicopathological features with E-cadherin (CDH1) gene-160 C>A promoter polymorphism in Turkish colorectal cancer patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu